Table 3.
Time to alleviation of symptoms for the intent-to-treat infected population
| Population and treatment (n) | Median time to alleviation (h) (95% CI) | Hazard ratio (97.5% CI)a |
|---|---|---|
| Overall | ||
| Peramivir | ||
| 300 mg (364) | 78.0 (68.4, 88.6) | 0.946 (0.793, 1.129)b |
| 600 mg (362) | 81.0 (72.7, 91.5) | 0.970 (0.814, 1.157)b |
| Oseltamivir (365) | 81.8 (73.2, 91.1) | |
| A/H1 | ||
| Peramivir | ||
| 300 mg (197) | 80.2 (69.3, 90.6) | 0.854 (0.672, 1.085) |
| 600 mg (200) | 83.6 (72.7, 101.9) | 0.927 (0.730, 1.176) |
| Oseltamivir (201) | 88.8 (73.1, 102.2) | |
| A/H3 | ||
| Peramivir | ||
| 300 mg (112) | 69.9 (54.4, 97.1) | 1.039 (0.745, 1.448) |
| 600 mg (108) | 70.6 (47.7, 91.9) | 0.958 (0.687, 1.335) |
| Oseltamivir (108) | 75.1 (63.4, 92.6) | |
| B | ||
| Peramivir | ||
| 300 mg (21) | 55.3 (43.9, 86.4) | 0.445 (0.202, 0.982) |
| 600 mg (26) | 92.8 (57.4, 116.1) | 0.706 (0.341, 1.460) |
| Oseltamivir (23) | 92.7 (70.2, 138.5) |
a
Hazard ratios compared to the oseltamivir group were estimated using Cox proportional-hazards models, which were adjusted for current smoking behavior, composite symptom score at baseline, country/region, influenza virus type, sex, complications, and previous therapy.
b
Both peramivir groups were noninferior to the oseltamivir group, with a noninferiority margin of 0.170.